ChromaDex Corp (NAGE) - EV/EBITDA Multiple
Stable chemical raw material supply chains guarantee the product quality of Chromadex Corp. This EV/EBITDA chart confirms a search for market equilibrium, where the metric stands at 20.38. B2B segment expansion via Niagen and patent protection enable the company to maintain premium pricing, creating a positive outlook for the company's capitalization.
Analytical breakdowns for ChromaDex Corp. (NAGE)
- stock price and consensus target price:
- market capitalization indicators:
- issuer book value statistics:
- company liabilities and liquidity data:
- business earnings and investment ratios data:
NAGE - Company Net Income|Expected Profit Chromadex Corp|NAGE - Price to Earnings Multiple|Projected Price to Earnings Chromadex Corp|NAGE - Company Value to Earnings Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ChromaDex Corporation|NAGE - Operating income before deduction of amortization|Net earnings per share (EPS TTM) ChromaDex|NAGE - Net earnings per share for the last 12 months|Quarterly EPS earnings growth niagenbioscience.com|NAGE - Earnings per share increase in current year|Net earnings per share growth forecast for next year Chromadex Corp
Summary company analysis:ChromaDex Corporation (NAGE)
To objectively measure the operational efficiency of Chromadex Corp (NAGE), investors must strip away the impact of taxes and debt load on net income. By analyzing the EV/EBITDA chart, which compares the total enterprise value to operating income, one can assess the productivity of the cellular metabolism R&D pipeline relative to the issuer's market capitalization and debt.
Competitors of Chromadex Corp
Intuitive Surgical Inc - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation DHR|Becton Dickinson & Co - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio steris.com STE|West Pharmaceutical Services, Inc. (WST) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation BAX|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Masimo Personal Health|Stevanato Group Corp (STVN) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio TFX (Teleflex Incorporated)|Enterprise Value to Operating Income Before Depreciation Ratio MMSI|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Envista NVST|Business Value to Operating Income Before Depreciation ICUI|XRAY: Enterprise Value to EBITDA Ratio|LMAT - EV/EBITDA Multiple|AtriCure, Inc. (ATRC) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio staar.com|ZIMV (ZimVie) - EV/EBITDA Multiple|Company Value to EBITDA AngioDynamics Inc ANGO|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cerus Corp (CERS)|Teknova Inc - Enterprise Value to Operating Income Before Depreciation|Monogram Technologies - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio STSS (Sharps Technology Inc)|INFU - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio Utah Medical Products Inc. UTMD|KRMD: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Nyxoah S.A|MBOT (Microbot Medical Inc.) - EV/EBITDA Multiple|PDEX: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Zentek (ZTEK)|ELUT (Elutia Inc) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Milestone Scientific Corp MLSS|NEXGEL Inc (NXGL) - Company Value to EBITDA|RVP - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Harvard Bioscience Inc. (HBIO) - Enterprise Value to EBITDA Ratio|FEMY: EV/EBITDA Multiple|Meihua Medical Technologies Co., Ltd. (MHUA) - EV/EBITDA Multiple|POAI (Predictive Oncology Inc) - EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation CJMB (Callan JMB Corp)|EV/EBITDA Multiple ATRI|NURO - Company Value to EBITDA
